Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24059282 | 0.79 | ALDH1A1 (0.46) | JAK2JAK1JAK3ALDH1A1KDM4E | |
| SCHEMBL1561268 | 0.77 | MEN1 (0.35) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL3220451 | 0.65 | CA1 (0.45) | KDM4EHTR2A | |
| SCHEMBL387126 | 0.65 | — | — | |
| SCHEMBL5005063 | 0.63 | — | — | |
| SCHEMBL22408378 | 0.63 | — | — | |
| SCHEMBL20641822 | 0.63 | CA12 (0.48) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL21885778 | 0.63 | KDM4E (0.34) | JAK2JAK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL24367859 | 0.63 | HTR2A (0.33) | JAK2JAK1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2759554 | 0.61 | L3MBTL1 (0.38) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565475-B1 | DIAZINOPYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20050261284-A1 | Diazinopyrimidines | CHEN JIAN J | 2005-11-24 | — | — | US | disclosed |
| US-6943158-B2 | Diazinopyrimidines | ROCHE PALO ALTO LLC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | HOFFMANN-LA ROCHE INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261284-A1 | Diazinopyrimidines | MAPK6, MAPK1, MAP2K6 | JAK2 284/4885JAK1 526/4885JAK3 1368/4885 |
| US-20040097493-A1 | For preparing medicaments useful for the therapy of the p38 MAP kinase and FGFR kinase mediated diseases and conditions | FGFR1, MAPK1, FGF1 | JAK2 52/4885JAK1 23/4885JAK3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.